Dyne Therapeutics (DYN) Operating Leases (2021 - 2026)

Dyne Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $14.3 million for Q1 2026.

• In Q1 2026, Operating Leases fell 21.67% year-over-year to $14.3 million; the TTM figure through Mar 2026 stood at $14.3 million (down 21.67% YoY), while the FY2025 annual figure was $15.3 million, down 20.14% from the prior year.
• Operating Leases was $14.3 million for Q1 2026 at Dyne Therapeutics, down from $15.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $28.1 million in Q1 2022 to a low of $14.3 million in Q1 2026.
• Historically, Operating Leases has averaged $21.6 million across 5 years, with a median of $21.9 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases surged 6685.36% in 2022, then fell 21.67% in 2026.
• A 5-year view of Operating Leases shows it stood at $25.9 million in 2022, then fell by 12.28% to $22.7 million in 2023, then retreated by 15.67% to $19.1 million in 2024, then slipped by 20.14% to $15.3 million in 2025, then declined by 6.62% to $14.3 million in 2026.
• The last three Operating Leases figures came in at $14.3 million (Q1 2026), $15.3 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.